Lornoksikam
![]() | |
![]() | |
Klinički podaci | |
---|---|
Prodajno ime | Lorcam, Xafon |
Drugs.com | Monografija |
Način primene | Intravenozno, oralno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 3-5 h |
Identifikatori | |
CAS broj | 70374-39-9 ![]() |
ATC kod | M01AC05 (WHO) |
PubChem | CID 5282204 |
DrugBank | DB06725 ![]() |
ChemSpider | 4445392 ![]() |
Hemijski podaci | |
Formula | C13H10ClN3O4S2 |
Molarna masa | 371,819 |
SMILES
| |
InChI
| |
Lornoksikam je organsko jedinjenje, koje sadrži 13 atoma ugljenika i ima molekulsku masu od 371,819 Da.[1][2][3][4][5][6][7]
Osobine
Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 6 |
Broj donora vodonika | 2 |
Broj rotacionih veza | 2 |
Particioni koeficijent[8] (ALogP) | 1,9 |
Rastvorljivost[9] (logS, log(mol/L)) | -3,8 |
Polarna površina[10] (PSA, Å2) | 136,2 |
Reference
- ^ Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. PMID 8706598
- ^ Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. PMID 8630629
- ^ Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. PMID 12879104
- ^ Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. PMID 9646006
- ^ Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. PMID 8162655
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126. уреди
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889
. PMID 18048412. doi:10.1093/nar/gkm958. уреди
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. уреди
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Lornoxicam
![]() | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |